Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis Healthcare...

    Fortis Healthcare board clears RHT portfolio acquisition for Rs 4,650 crore

    Written by Ruby Khatun Khatun Published On 2017-11-15T14:09:07+05:30  |  Updated On 18 Aug 2021 12:11 PM IST

    New Delhi: Fortis Healthcare board has approved the proposed acquisition of the entire portfolio of Singapore-listed RHT Health Trust (RHT) for an enterprise value of around Rs 4,650 crore, the company said.


    The step is part of a restructuring initiative aimed at consolidating the entire Indian asset portfolio comprising various clinical establishments and two operating hospitals of RHT Health Trust into Fortis.


    Fortis and RHT have inked a pact proposing the acquisition of all the securities of RHT's entities in India holding, clinical entities and businesses via the purchase of securities for an enterprise value of around Rs 4,650 crore, Fortis said in a statement.


    This includes Rs 1,152 crore of debt of RHT as on date, it added.


    "This restructuring is a significant initiative and will integrate RHT's entire India-based asset portfolio into Fortis while also improving the overall financial health of the business," Fortis Healthcare CEO Bhavdeep Singh said.


    The proposed purchase of securities will be conducted on an arm's length basis, he added.


    "The proposed transaction would be funded by Fortis with a combination of equity, quasi-equity and/or debt. Fortis has an enabling resolution in place to raise capital of up to Rs 5,000 crore," Singh said.


    The proposed transaction will be subject to the satisfaction of conditions precedent, including regulatory and shareholder approvals by Fortis, approvals by RHT unitholders and other approvals as may be required, he added.


    Fortis has an indirect interest of 29.76 percent in RHT.


    The term sheet signed by both Fortis and the trustee-manager of RHT is intended to set out the basis for further discussion in respect of the proposed transaction.


    Both Fortis and RHT have entered into an exclusivity period for 60 days commencing from the date of the term sheet with a view to executing definitive agreements for the proposed transaction.


    Fortis has also entered into hospital and medical services agreements with entities held by RHT under which it pays service fees to such entities for services rendered.


    For 2017-18, the net cumulative service fees to be paid by Fortis to RHT is estimated to be around Rs 270 crore.


    "Upon completion of the securities acquisition, the service fees that Fortis was paying will be completely eliminated, thereby improving significantly its operating profitability," Fortis said.

    AcquisitionBhavdeep SinghboardclearsFortisFortis HealthcareFortis Hospitalhospitalhospitals IndiaIndian asset portfolioRHT Health TrustRHT portfolio
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok